84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs011210048
05/11/202105/11/2021Cardiac Sarcoidosis Multi-Center Randomized Controlled TrialCardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT Cardiac Sarcoidosis
Cardiac Sarcoidosis
Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either:

1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or

2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP
Toshiyuki NagaiNULLPending>= 18age oldNot applicableBoth194Phase 3Canada;United States;United Kingdom;Japan
2JPRN-jRCTs041180111
16/12/201619/03/2019Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study Cardiac sarcoidosis
Cardiac sarcoidosis
After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 monthsMurohara ToyoakiNULLComplete>= 20age oldNot applicableBoth50Phase 3Japan